Zibotentan and dapagliflozin to treat chronic kidney disease with high proteinuria.

CL202600880A1Pending Publication Date: 2026-07-10ASTRAZENECA AB

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202600880
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-02-07
Filing Date: 2026-03-25
Publication Date: 2026-07-10

Application Information

Patent Timeline

07 Feb 2024

Priority

25 Mar 2026

Application

CL202600880

10 Jul 2026

Publication

CL202600880A1

IPC: A61K31/351; A61K31/497; A61K31/7034; A61P9/12; A61P13/12

CPC: A61K31/497; A61K31/7034; A61P13/12; A61K2300/00; A61K31/351; A61P9/12; A61P9/04; A61P3/06

Inventors: AMBERY Philip; GREASLEY Peter

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Methods are described for treating chronic kidney disease with high proteinuria and / or at least one associated disease, disorder, or condition in patients using a fixed-dose combination of zibotentan and dapagliflozin.

Need to check novelty before this filing date? Find Prior Art